CoChat

Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting

Open access
Lu, Bing, Huang, Xiaojia, Mo, Jingxin, Zhao, Wei · 2016 · Frontiers in Pharmacology
Cited by 76

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The theory of cancer stem-like cell (or cancer stem cell, CSC) has been established to explain how tumor heterogeneity arises and contributes to tumor progression in diverse cancer types. CSCs are believed to drive tumor growth and elicit resistance to conventional therapeutics. Therefore, CSCs are becoming novel target in both medical researches and clinical studies. Emerging evidences showed that nanoparticles effectively inhibit many types of CSCs by targeting various specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) and signaling pathways (Notch, Hedgehog, and TGF-β), which are critically involved in CSC function and maintenance. In this review, we briefly summarize the current status of CSC research and review a number of state-of-the-art nanomedicine approaches targeting CSC. In addition, we discuss emerging therapeutic strategies using epigenetic drugs to eliminate CSCs and inhibit cancer cell reprogramming.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2016.00084

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer drug resistance: an evolving paradigm

    Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 4×

    “…chemotherapies owing to various enhanced features, including ATP-binding cassette (ABC) transporter proteins, aldehyde dehydrogenase (ALDH) activity, anti-apoptotic proteins, DNA damage repair and activation of key pro-survival signaling molecules such as Notch and NF-κB (Holohan et al., 2013).”
    BackgroundInfluential
  • Sequential cancer mutations in cultured human intestinal stem cells

    Drost, J., van Jaarsveld, R. H., Ponsioen, B., Zimberlin, C., van Boxtel, R., Buijs, A., Sachs, N., Overmeer, R. M., Offerhaus, G. J., Begthel, H., et al. (2015) · Nature · doi:10.1038/nature14415 · Cited by 1,067 · cited 1×

    “Drost et al. (2015) depleted four of the genes (APC, P53, KRAS, and SMAD4) with CRISPR/Cas9 technology in cultured human intestinal stem cells formed organoids.”
    Background
  • BET inhibitor resistance emerges from leukaemia stem cells

    Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · cited 1×

    “These findings indicate the potential therapeutic strategy using MLL2 inhibitor in combination of lapatinib delivered by nanocarrier to treat metastatic breast cancer patients (Matkar et al., 2015).”
    Background
  • Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions

    Vazquez-Martin, A., López-Bonetc, E., Cufí, S., Oliveras-Ferraros, C., Del Barco, S., Martin-Castillo, B., & Menendez, J. A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.04.003 · Cited by 66 · cited 1×

    “Exactly as Oct4, the transcription factor which also contributes to premalignant carcinoma in situ, as well as high expressing in blastocyst and cancer cell cDNA but low expressing in normal tissue cDNA (Vazquez-Martin et al., 2011).”
    Background
  • MLL leukemia induction by genome editing of human CD34+ hematopoietic cells

    Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646398 · Cited by 60 · cited 1×

    “Recently, Buechele et al. (2015) generated endogenous MLL-AF9 and MLL-ENL oncogenes through insertional mutagenesis into primary human hematopoietic stem and progenitor cells (HSPCs) derived from human umbilical cord blood.”
    Background

Show all 5 references

Cited by

See all 76

Metadata

Authors
Lu, B., Huang, X., Mo, J., & Zhao, W.
Venue
Frontiers in Pharmacology
Published
2016-04-12
Volume
7
Pages
84-84
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2325102527
Cited by
76
References
5
FWCI
4.51
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. https://app.cochat.ai/papers/10.3389/fphar.2016.00084
The paper
Lu, B., Huang, X., Mo, J., & Zhao, W. (2016). Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2016.00084

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.